Developing integrated single-use upstream and downstream platform processing options for allogeneic cell therapy applications: Linking the stirred tank bioreactor to the TFF

Cytotherapy ◽  
2017 ◽  
Vol 19 (5) ◽  
pp. S124
Author(s):  
D. Popova ◽  
P. Dhadda ◽  
M. Bell ◽  
P. Amable ◽  
J. Murrell ◽  
...  
Keyword(s):  
Cell Therapy ◽  
Stirred Tank ◽  
Stirred Tank Bioreactor ◽  
Allogeneic Cell ◽  
Allogeneic Cell Therapy ◽  
Single Use

scholarly journals Allogeneic cell therapy bioprocess economics and optimization: Single‐use cell expansion technologies

2013 ◽  
Vol 111 (1) ◽  
pp. 69-83 ◽  
Author(s):  
Ana S. Simaria ◽  
Sally Hassan ◽  
Hemanthram Varadaraju ◽  
Jon Rowley ◽  
Kim Warren ◽  
...  
Keyword(s):  
Cell Therapy ◽  
Cell Expansion ◽  
Allogeneic Cell ◽  
Allogeneic Cell Therapy ◽  
Single Use

scholarly journals Safety and Efficacy of Allogeneic Cell Therapy in Infarcted Rats Transplanted With Mismatched Cardiosphere-Derived Cells

Circulation ◽  
2012 ◽  
Vol 125 (1) ◽  
pp. 100-112 ◽  
Author(s):  
Konstantinos Malliaras ◽  
Tao-Sheng Li ◽  
Daniel Luthringer ◽  
John Terrovitis ◽  
Ke Cheng ◽  
...  
Keyword(s):  
Cell Therapy ◽  
Safety And Efficacy ◽  
Allogeneic Cell ◽  
Allogeneic Cell Therapy

Similar effect of autologous and allogeneic cell therapy for ischemic heart disease: results from a meta-analysis of large animal studies

2013 ◽  
Vol 34 (suppl 1) ◽  
pp. P1462-P1462
Author(s):  
S. J. Jansen Of Lorkeers ◽  
J. E. C. Eding ◽  
T. I. G. Van Der Spoel ◽  
H. M. Vesterinen ◽  
S. Koudstaal ◽  
...  
Keyword(s):  
Heart Disease ◽  
Cell Therapy ◽  
Ischemic Heart Disease ◽  
Animal Studies ◽  
Meta Analysis ◽  
Ischemic Heart ◽  
Large Animal ◽  
Allogeneic Cell ◽  
Allogeneic Cell Therapy

Abstract WP338: Combined Coiling and Allogeneic Mesenchymal Stem/Stromal Cell Therapy Could be a More Cost-effective Alternative to Coiling Alone

Stroke ◽  
2016 ◽  
Vol 47 (suppl_1) ◽  
Author(s):  
Amin Adibi ◽  
Arindom Sen ◽  
Alim P Mitha
Keyword(s):  
Sensitivity Analysis ◽  
Cell Therapy ◽  
Markov Model ◽  
Cost Effective ◽  
Effective Alternative ◽  
Sensitivity Testing ◽  
Allogeneic Cell ◽  
Allogeneic Cell Therapy ◽  
Cost Effective Treatment ◽  
Cost Effective Alternative

Introduction: Recurrence of intracranial aneurysms following endovascular therapy in 20% of patients remains the only major disadvantage of this treatment. For this reason, a significant amount of research has been carried out, focused on reducing the incidence of recurrence. In recent years, a variety of cell therapy modalities using fibroblasts, smooth muscle cells, endothelial progenitor cells and Mesenchymal Stem/Stromal Cells (MSCs) have been tested in animal models as a means to improve the outcome of the treatment. However, it remains unclear whether preventing recurrence using cell therapy is a more cost-effective alternative to retreating recanalized aneurysms. In this study, we have used a Markov model approach to determine efficacy thresholds at which combined coiling and cell therapy becomes a more cost-effective treatment than coiling alone. Hypothesis: Combined coiling and cell therapy will be more cost-effective than coiling alone, if it reduces the need for retreatment by 50% or more. Methods: The cell therapy was assumed to be aimed at reducing the need for retreatment. A Markov model was used to compare coiling alone with combined coiling and autologous/allogeneic cell therapy. Model inputs were mostly taken from meta-analyses. Sensitivity analysis was performed to predict efficacy thresholds that make cell therapy more cost-effective than coiling alone. Robustness of the model was assessed through further sensitivity testing focused on variables with the highest impact on the outcome. Results: Sensitivity analysis showed that coiling with autologous cell therapy becomes more cost-effective than coiling alone, if it reduces the need for retreatment by 39.9% or more. When allogeneic cell are used, a reduction of 13.3% or more in the need for retreatment is enough the make combined coiling and cell therapy more cost-effective. Conclusions: Our preliminary analysis suggests that efficacy thresholds at which combined coiling and cell therapy becomes more cost-effective than coiling alone are modest - especially for allogeneic MSC therapies. This makes combined coiling and cell therapy a viable alternative to the current standard-of-care from a cost-utility standpoint, and justifies further research and investment in the field.

scholarly journals Human mesenchymal stem cell sheets in xeno-free media for possible allogenic applications

2019 ◽  
Vol 9 (1) ◽  
Author(s):  
Kyungsook Kim ◽  
Sophia Bou-Ghannam ◽  
Hallie Thorp ◽  
David W. Grainger ◽  
Teruo Okano
Keyword(s):  
Stem Cell ◽  
Cell Therapy ◽  
Subcutaneous Tissue ◽  
Cell Sheet ◽  
Human Mesenchymal Stem Cell ◽  
Human Umbilical Cord ◽  
Target Tissue ◽  
Post Transplantation ◽  
Allogeneic Cell ◽  
Allogeneic Cell Therapy

Abstract Cell-based therapies are increasingly focused on allogeneic stem cell sources because of several advantages in eliminating donor variability (e.g., aging and disease pathophysiology) affecting stem cell quality and in cell-banked sourcing of healthy donors to enable “off-the-shelf” products. However, allogeneic cell therapy is limited by host patient immunologic competence and inconsistent performance due to cell delivery methods. To address allogeneic cell therapy limitations, this study developed a new allogeneic stem cell sheet using human umbilical cord mesenchymal stem cells (hUC-MSC) that present low antigenicity (i.e., major histocompatibility complex, MHC). Optimal conditions including cell density, passage number, and culture time were examined to fabricate reliable hUC-MSC sheets. MHC II antigens correlated to alloimmune rejection were barely expressed in hUC-MSC sheets compared to other comparator MSC sheets (hBMSC and hADSC). hUC-MSC sheets easily graft spontaneously onto subcutaneous tissue in immune-deficient mice within 10 minutes of placement. No sutures are required to secure sheets to tissue because sheet extracellular matrix (ECM) actively facilitates cell-target tissue adhesion. At 10 days post-transplantation, hUC-MSC sheets remain on ectopic target tissue sites and exhibit new blood vessel formation. Furthermore, implanted hUC-MSC sheets secrete human HGF continuously to the murine target tissue. hUC-MSC sheets described here should provide new insights for improving allogenic cell-based therapies.

scholarly journals Allogeneic Cell Therapy

2015 ◽  
Vol 116 (1) ◽  
pp. 12-15 ◽  
Author(s):  
Vasileios Karantalis ◽  
Ivonne Hernandez Schulman ◽  
Wayne Balkan ◽  
Joshua M. Hare
Keyword(s):  
Cell Therapy ◽  
Allogeneic Cell ◽  
Allogeneic Cell Therapy

scholarly journals Allogeneic cell therapy for patients who relapse after autologous stem cell transplantation

2001 ◽  
Vol 7 (4) ◽  
pp. 230-238 ◽  
Author(s):  
David L Porter ◽  
Selina M Luger ◽  
Kathleen M Duffy ◽  
Edward A Stadtmauer ◽  
Ginna Laport ◽  
...  
Keyword(s):  
Stem Cell ◽  
Cell Therapy ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Autologous Stem Cell Transplantation ◽  
Allogeneic Cell ◽  
Allogeneic Cell Therapy
Sign in / Sign up

Export Citation Format

Share Document